Update on Percutaneous Treatment for HFrEF: A Great Armamentarium for a Poor Ventricular Function

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Devices

Background:

• Pharmacological therapy is standard for heart failure with reduced ejection fraction (HFrEF).
• Some heart failure (HF) patients have specific phenotypes, like valvular heart disease, requiring non-pharmacological interventions.
• High-level patient care necessitates addressing prognostic relevance through advanced treatments.

Purpose of the Study:

• To provide a clinical overview of transcatheter devices for HFrEF.
• To focus on the selection criteria for these devices in interventional cardiology.
• To review current data on non-pharmacological treatment options for HF phenotypes.

Main Methods:

• Review of clinical data on transcatheter devices.
• Analysis of selection criteria for interventional cardiology procedures.
• Focus on symptomatic HF patients with specific phenotypes.

Main Results:

• Transcatheter devices offer alternative treatment options for select HFrEF patients.
• Clinical and anatomical criteria are crucial for device selection.
• Percutaneous techniques are evolving for HF management.

Conclusions:

• Transcatheter devices are an important part of the interventional cardiologist's toolkit for HFrEF.
• Careful patient selection based on clinical and anatomical factors is essential for successful outcomes.
• This review highlights the growing role of percutaneous interventions in managing complex HF cases.